rizatriptan benzoate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
rizatriptan benzoate: clinical details
Prescribing considerations
- Confirm a clear migraine diagnosis; do not use for atypical headache or migraine prevention.
- Assess cardiovascular risk before prescribing where unrecognised coronary disease is plausible.
- Selected products are licensed for adults; safety and efficacy are not established for people under 18, and evidence in older adults is limited.
- Review renal and hepatic function, cardiovascular history, blood pressure, interacting medicines and headache-treatment frequency.
- Consider medication-overuse headache when headaches become frequent or daily during repeated acute-treatment use.
Contraindications and cautions
- Hypersensitivity to rizatriptan or product excipients
- Concurrent monoamine oxidase inhibitor treatment or use within the product-specified washout period
- Severe renal or hepatic impairment
- Previous stroke or transient ischaemic attack
- Moderately severe or severe hypertension, or untreated mild hypertension
- Established coronary artery disease, ischaemic heart disease or Prinzmetal angina
- Peripheral vascular disease
- Concurrent ergot derivatives or other 5-HT1B/1D agonists
Monitoring
- Clinical response and adverse effects
- New, intense or persistent chest or throat symptoms
- Blood pressure and cardiovascular symptoms where clinically indicated
- Symptoms of serotonin syndrome with serotonergic medicines
- Headache frequency and possible medication-overuse headache
Clinical pharmacology
Rizatriptan is a selective 5-HT1B/1D receptor agonist. It undergoes substantial first-pass metabolism, principally through monoamine oxidase-A, and has a relatively short plasma half-life. An active metabolite is formed in small amounts but contributes little to the overall effect.
Formulation and product differences
- Conventional tablets are swallowed with liquid; food delays absorption.
- Orodispersible tablets and oral lyophilisates dissolve on the tongue and do not require liquid.
- Selected mouth-dissolving products contain aspartame, which is relevant in phenylketonuria.
- Lactose content differs between selected products; check the specific formulation when excipient intolerance matters.
- Mouth-dissolving formulations may reach peak concentration later than conventional tablets.
rizatriptan benzoate preparations and strengths
Dispersible tablet
Route: Oral
Strengths: 10 mg
Tablet
Route: Oral
Strengths: 5 mg, 10 mg
rizatriptan benzoate interactions
Important interactions include:
Monoamine oxidase inhibitors, including linezolid
They can substantially increase rizatriptan exposure and the risk of vasoconstriction or hypertension; concurrent use is contraindicated under the selected product information.
Other triptans
Combining rizatriptan with another 5-HT1B/1D agonist can cause additive vasoconstriction and is contraindicated.
Ergotamine and ergot derivatives
Combined use can increase coronary vasoconstriction and hypertensive effects and is contraindicated.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.